| abstract |
Compounds of the formula (I) (see formula (I)) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof are described; the method for inhibiting aspartyl protease is also described, and in particular, the methods of treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods for inhibiting Human Immunodeficiency Virus, plasmepine, cathepsin D and protozoal enzymes, also described methods for the treatment of diseases or neurodegeneratives using the compounds of the formula (I) in combination with a cholinesterase inhibitor or a muscarinic antagonist. |